Cytokinetics, Incorporated (CYTK) News
Filter CYTK News Items
CYTK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CYTK News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CYTK News From Around the Web
Below are the latest news stories about CYTOKINETICS INC that investors may wish to consider to help them evaluate CYTK as an investment opportunity.
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA. Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the C |
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of 52,188 shares of common stock, 33,885 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 3,189 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 9 employees, whose employment commenced in December 2024 |
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathySOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP). “With regulatory filings for aficamten already under review in |
Why Cytokinetics Stock Was a Nearly 5% Winner TodayThis is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Cytokinetics originally sold those rights to Corxel in 2020. Additionally, it can reap royalties on future sales of the drug in Greater China. |
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater ChinaSOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM. In 2020, CORXEL (formerly Ji Xing) acq |
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)Key Insights Using the 2 Stage Free Cash Flow to Equity, Cytokinetics fair value estimate is US$48.61 With US$46.36... |
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Cytokinetics Initiates Confirmatory Study on Heart Failure DrugCYTK opens enrollment in the phase III COMET-HF study on omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction. |
Sector Update: Health Care Stocks Mixed Late AfternoonHealth care stocks were mixed in late Tuesday afternoon trading with the NYSE Health Care Index addi |
FDA Accepts Cytokinetics' Application for Cardiovascular DrugCYTK's NDA is seeking approval for the lead pipeline candidate, aficamten, which the FDA accepted and assigned a target action date of Sept. 26, 2025. |